HTG Molecular Diagnostics, Inc. HTGMQ
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -28.21% | -28.52% | -21.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.21% | -28.52% | -21.00% | -- | -- |
| Cost of Revenue | -0.64% | 5.17% | 24.80% | -- | -- |
| Gross Profit | -85.80% | -163.81% | -550.54% | -- | -- |
| SG&A Expenses | -20.32% | -8.68% | 6.73% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.69% | -3.37% | 13.57% | -- | -- |
| Operating Income | 6.30% | -8.22% | -30.69% | -- | -- |
| Income Before Tax | -7.27% | -26.05% | -36.14% | -- | -- |
| Income Tax Expenses | -37.75% | -51.34% | -61.33% | -- | -- |
| Earnings from Continuing Operations | -7.22% | -25.95% | -36.01% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.22% | -25.95% | -36.01% | -- | -- |
| EBIT | 6.30% | -8.22% | -30.69% | -- | -- |
| EBITDA | 5.43% | -9.26% | -33.74% | -- | -- |
| EPS Basic | 39.53% | 14.34% | 6.89% | -- | -- |
| Normalized Basic EPS | 48.67% | 27.41% | 11.03% | -- | -- |
| EPS Diluted | 39.53% | 14.34% | 6.89% | -- | -- |
| Normalized Diluted EPS | 48.67% | 27.41% | 11.03% | -- | -- |
| Average Basic Shares Outstanding | 106.10% | 53.82% | 48.31% | -- | -- |
| Average Diluted Shares Outstanding | 106.10% | 53.82% | 48.31% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |